amTCO, a new trans-cyclooctene derivative to study drug-target interactions in cells

Journal: Chemical Communications

Published: 2021-02-01

DOI: 10.1039/d0cc06709a

Affiliations: 4

Authors: 9

Go to article
Institutions Share
Cellzome GmbH, Germany 0.50
European Molecular Biology Laboratory (EMBL), Germany 0.22
GlaxoSmithKline plc. (GSK), United Kingdom (UK) 0.22
Oregon Health and Science University (OHSU), United States of America (USA) 0.06